Diagnosis and Management of Endomyocardial Fibrosis

Andrea Beaton; Ana Olga Mocumbi

doi:10.1016/j.ccl.2016.08.005

Diagnosis and Management of Endomyocardial Fibrosis

Cardiol Clin. 2017 Feb;35(1):87-98. doi: 10.1016/j.ccl.2016.08.005.

Authors

Andrea Beaton¹, Ana Olga Mocumbi²

Affiliations

¹ Division of Cardiology, Children's National Health System, 111 Michigan Avenue, Northwest, Washington, DC 20010, USA. Electronic address: abeaton@childrensnational.org.
² Chronic and Non-Communicable Disease Division, National Health Institutes and Eduardo Mondlane University, Avenida do Zimbábew, Maputo, Mozambique.

PMID: 27886792
DOI: 10.1016/j.ccl.2016.08.005

Abstract

Endomyocardial fibrosis (EMF) remains an important cause of restrictive cardiomyopathy worldwide. Patients cluster in specific geographic locations and are almost universally living in extreme poverty. Specific etiology remains elusive and is likely multifactorial. Untreated EMF has a very poor prognosis. Medical management can mitigate symptoms for a time but has no curative benefit. Early surgical interventions may improve survival but are not readily available in most EMF-endemic regions. Increased awareness, advocacy, and research are needed to further understand this neglected tropical cardiomyopathy and to improve survival of those affected.

Keywords: Endomyocarial fibrosis; Heart failure; Neglected diseases; Restrictive cardiomyopathy.

Publication types

Review

MeSH terms

Disease Management*
Endomyocardial Fibrosis* / diagnosis
Endomyocardial Fibrosis* / epidemiology
Endomyocardial Fibrosis* / therapy
Global Health
Humans
Incidence
Prognosis